EYPT — Eyepoint Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $437.80m
- $66.89m
- $43.27m
- 33
- 18
- 15
- 10
Annual income statement for Eyepoint Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 34.4 | 36.9 | 41.4 | 46 | 43.3 |
| Cost of Revenue | |||||
| Gross Profit | 28.6 | 28.8 | 33.1 | 41.4 | 39.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 72.6 | 90.2 | 143 | 122 | 189 |
| Operating Profit | -38.2 | -53.2 | -101 | -76.4 | -146 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -45.4 | -58.4 | -102 | -70.7 | -131 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -45.4 | -58.4 | -102 | -70.8 | -131 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -45.4 | -58.4 | -102 | -70.8 | -131 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -45.4 | -58.4 | -102 | -70.8 | -131 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.42 | -2.1 | -2.14 | -1.8 | -2.32 |